Palvella Therapeutics (PVLA) Capital Expenditures (QoQ) (2014 - 2023)
Palvella Therapeutics (PVLA) Capital Expenditures (QoQ) (2014 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -118.84% |
| Sep 30, 2023 | 2.99% |
| Jun 30, 2023 | 39.58% |
| Mar 31, 2023 | -95.25% |
| Dec 31, 2022 | 202.33% |
| Sep 30, 2022 | -256.92% |
| Jun 30, 2022 | 61.70% |
| Mar 31, 2022 | 13.74% |
| Dec 31, 2021 | -2.29% |
| Sep 30, 2021 | 52.84% |
| Jun 30, 2021 | 717.86% |
| Mar 31, 2021 | -95.16% |
| Dec 31, 2020 | 168.81% |
| Sep 30, 2020 | -179.17% |
| Jun 30, 2020 | -44.94% |
| Mar 31, 2020 | 63.86% |
| Dec 31, 2019 | 406.90% |
| Sep 30, 2019 | -75.13% |
| Jun 30, 2019 | 671.07% |
| Mar 31, 2019 | -78.58% |